---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017748"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:38:47.502485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric issues 458K shares at $0.94 to waive equity line restriction; no proceeds

## Summary
- Issued 458,000 shares to institutional investors at $0.94 per share in registered direct offering.
- Offering is to permanently waive variable rate transaction limitation from December 2023 Inducement Letters.
- Company will not receive any net proceeds; waiver enables use of existing equity line of credit.
- Company restricted from issuing additional shares for 30 days or until 15 million shares trade.

## SEC filing metadata
- accession: 0001493152-24-017748
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/0001493152-24-017748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017748
- JSON: https://secwatch.observer/filing/0001493152-24-017748.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017748.txt

## Key facts
- Material Agreements
  Enveric Biosciences, Inc. entered into Purchase Agreements with certain institutional investors valued at at a deemed offering price of $0.94 per share (effective 2024-05-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: at a deemed offering price of $0.94 per share
  - Effective: 2024-05-03
  source text: On May 3, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreements”) for the issuance in a registered direct offering of an aggregate of 458,000 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/0001493152-24-017748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.